Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Company Overview

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors. By combining gene-editing technologies with optimized cell expansion processes, the company aims to enhance tumor targeting, persistence and safety profiles. Its platform supports rapid manufacturing and scalable production, potentially enabling broader patient access and faster clinical development timelines.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Artiva Biotherapeutics operates in key biopharma hubs across North America and Europe. The company’s management team brings collective expertise in immuno-oncology, cell therapy manufacturing and clinical development, positioning Artiva to advance its candidate programs through pivotal trials and, ultimately, regulatory approval.

Key Stats

• Today's Range: $11.00 to $12.09
• 50-Day Range: $4.80 to $13.39
• 52-Week Range: $1.47 to $14.53
• Volume: 97,562 shs
• Average Volume: 223,511 shs
• Market Capitalization: $291.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.67
• Consensus Rating: Moderate Buy

Artiva Biotherapeutics Stock Analysis - MarketRank™

Artiva Biotherapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 517th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Artiva Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Artiva Biotherapeutics has a consensus price target of $18.67, representing about 76.1% upside from its current price of $10.60.

Amount of Analyst Coverage

Artiva Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Artiva Biotherapeutics are expected to grow in the coming year, from ($3.33) to ($2.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artiva Biotherapeutics is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artiva Biotherapeutics is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Artiva Biotherapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.76% of the float of Artiva Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Artiva Biotherapeutics has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artiva Biotherapeutics has recently increased by 0.19%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artiva Biotherapeutics does not currently pay a dividend.

Dividend Growth

Artiva Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: -0.01

News Sentiment

Artiva Biotherapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Artiva Biotherapeutics this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for ARTV on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Artiva Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Artiva Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.40% of the stock of Artiva Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Artiva Biotherapeutics has minimal institutional ownership at this time.

ARTV Stock Analysis - Frequently Asked Questions

How have ARTV shares performed this year?

Artiva Biotherapeutics' stock was trading at $4.29 at the beginning of the year. Since then, ARTV stock has increased by 147.1% and is now trading at $10.60.

How were Artiva Biotherapeutics' earnings last quarter?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) posted its quarterly earnings results on Tuesday, March, 10th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.03.

When did Artiva Biotherapeutics IPO?

Artiva Biotherapeutics (ARTV) raised $209 million in an initial public offering on Friday, July 19th 2024. The company issued 13,920,000 shares at a price of $14.00-$16.00 per share.

Who are Artiva Biotherapeutics' major shareholders?

Top institutional shareholders of Artiva Biotherapeutics include Simplify Asset Management Inc. (0.09%) and Sanctuary Advisors LLC (0.09%). Insiders that own company stock include Yong-Jun Huh, Global Strategic Fund I Venbio and Fred Aslan.
View institutional ownership trends.

How do I buy shares of Artiva Biotherapeutics?

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Artiva Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

• Last Earnings: 3/10/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARTV
• Previous Symbol: NASDAQ:ARTV
• CIK: 1817241
• Web: www.artivabio.com
• Phone: (858) 267-4467
• Fax: N/A
• Employees: 81
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Artiva Biotherapeutics: $18.67
• High Price Target: $23.00
• Low Price Target: $15.00
• Potential Upside/Downside: +58.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.22%
• Return on Assets: -52.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.61
• Quick Ratio: 8.61

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 1,164.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.48 per share
• Price / Book: 2.63

Miscellaneous

• Outstanding Shares: 24,720,000
• Free Float: 19,428,000
• Market Cap: $291.10 million
• Optionable: N/A
• Beta: 2.86